EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers

Jinyang Zhang, Xiaomeng Sun, Qichen Zhou, Yingying Wei, Biao Chen, Junhui Jiao, Yu Du, Shepherd Wufoyrwoth iD, Haoze Chi, Yi Yang, Ping Wei, Yungen Xu iD und 2 weitere

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c01977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Jinyang Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, DNA-Directed DNA Polymerase, Enzyme Inhibitors. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polθ, a key enzyme mediating microhomology-mediated end joining (MMEJ), is overexpressed in multiple human cancers and represents a promising therapeutic target, particularly in tumors with homologous recombination (HR) deficiency. Herein, we report the discovery and optimization of a novel series of Polθ polymerase (Polθ-pol) inhibitors featuring an arylalkyne scaffold, which extends into a peripheral channel within the polymerase domain to enhance target engagement. Among the synthesized compounds, compound 20 exhibited potent inhibitory activity against Polθ-pol at a nanomolar level (IC50 = 1.3 nM), along with antiproliferative activity against the HR-deficient cancer cell lines, such as MDA-MB-436, Capan-1, and DLD-1 (BRCA2-/-). Moreover, compound 20 demonstrated favorable pharmacokinetic properties, with oral bioavailability values of 103.36% in mice and 63.71% in rats, respectively. In an MDA-MB-436 xenograft model, compound 20 significantly suppressed tumor growth without evident toxicity. These findings underscore the arylalkyne scaffold as a highly promising strategy for the development of orally active Polθ-targeted therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDNA-Directed DNA PolymeraseEnzyme InhibitorsHumansAnimalsDNA Polymerase thetaAdministration, OralMiceCell Line, TumorBiological AvailabilityStructure-Activity RelationshipRatsFemaleDrug DiscoveryCell ProliferationXenograft Model Antitumor AssaysRats, Sprague-Dawley

Substanzen

DNA Polymerase thetaAntineoplastic AgentsDNA-Directed DNA PolymeraseEnzyme Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
  • Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 211198, China.
  • Hefei Institute of Pharmaceutical Industry Co., Ltd., Hefei 230601, China.

ORCID-Profile: Shepherd Wufoyrwoth, Yungen Xu, Yi Zou, Qihua Zhu

Zitieren

APA

Zhang, J., Sun, X., Zhou, Q., Wei, Y., Chen, B., Jiao, J., Du, Y., Wufoyrwoth, S., Chi, H., Yang, Y., Wei, P., Xu, Y., Zou, Y., & Zhu, Q. (2026). Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01977

Vancouver

Zhang J, Sun X, Zhou Q, Wei Y, Chen B, Jiao J, et al. Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c01977

BibTeX
@article{Zhang2026,
  author = {Zhang, Jinyang and Sun, Xiaomeng and Zhou, Qichen and Wei, Yingying and Chen, Biao and Jiao, Junhui and Du, Yu and Wufoyrwoth, Shepherd and Chi, Haoze and Yang, Yi and Wei, Ping and Xu, Yungen and Zou, Yi and Zhu, Qihua},
  title = {Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c01977}
}
Kostenlos starten →